Mahkam Zanganeh - 09 Jun 2022 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role
Director
Signature
/s/ Kenneth B. Stratton, as Attorney-in-Fact
Issuer symbol
PLSE
Transactions as of
09 Jun 2022
Net transactions value
$0
Form type
4
Filing time
10 Jun 2022, 18:59:54 UTC
Previous filing
23 May 2022
Next filing
18 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PLSE Common Stock Exercise of in-the-money or at-the-money derivative security +86,668 +24% 442,168 09 Jun 2022 Direct F1, F2
holding PLSE Common Stock 27,000 09 Jun 2022 Immediate family member 1
holding PLSE Common Stock 14,000 09 Jun 2022 Immediate family member 2
holding PLSE Common Stock 107,074 09 Jun 2022 Immediate family member 3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLSE Warrant (right to buy) Purchase +86,668 86,668 09 Jun 2022 Common Stock 86,668 $2.05 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and the Prospectus Supplement and certain Current Reports on Form 8-K filed by the Issuer with the SEC.
F2 Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $2.05 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $2.05.